Sansure Biotech's (SHA:688289) subsidiary, Zhongshan Sansure Haiji Biopharmaceutical, completed the domestic drug filing for the recombinant human growth hormone injection's workshop at China's National Medical Products Administration, according to a Shanghai Stock Exchange filing on Tuesday.
The Chinese molecular diagnostics and genetic testing products manufacturer will build a new production line in Zhongshan Torch High-Tech Industrial Development Zone, China, for the product after the approval.
The company's shares slipped more than 1% in recent trade.